Plain-English translation of NCT07625007 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether shortwave therapy—a treatment that uses electromagnetic waves to stimulate tissue—can help relieve nerve damage symptoms caused by diabetes. About 202 people will participate, with half receiving the actual treatment and half receiving a placebo (sham treatment that looks identical but doesn't emit the energy). Researchers will measure whether this treatment reduces nerve pain, numbness, and tingling after five days of therapy.
Many people with diabetes develop nerve damage that causes pain, numbness, and tingling in their feet and legs, and standard medications don't always help. This trial exists to find out if shortwave therapy could be an effective new option for patients whose symptoms haven't improved with existing treatments.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will come to the hospital for five consecutive days. Each day, you'll sit and place both of your lower legs into a special shortwave therapy device for 20 minutes. Half of participants will receive the real treatment, and half will receive a placebo treatment that looks and feels identical but doesn't deliver the therapeutic energy. You'll be assessed at the start and one month after treatment ends to measure whether your nerve symptoms have improved.
AI-generated summary from trial data · Jun 20, 2026 · Not medical advice
China